These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 37119011)

  • 1. VEXAS: is it time to reshape the nosology of clonal hematopoiesis?
    Sujobert P; Largeaud L; Jamilloux Y; Heiblig M; Kosmider O
    Expert Rev Hematol; 2023; 16(7):495-499. PubMed ID: 37119011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
    Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
    Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy.
    Kanagal-Shamanna R; Beck DB; Calvo KR
    Annu Rev Pathol; 2024 Jan; 19():479-506. PubMed ID: 37832948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?
    Kusne Y; Fernandez J; Patnaik MM
    Semin Hematol; 2021 Oct; 58(4):226-229. PubMed ID: 34802544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal hematopoiesis in VEXAS syndrome.
    Blood; 2023 Jul; 142(3):306. PubMed ID: 37471106
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
    Osman A; Patel JL
    Clin Chem; 2021 Aug; 67(8):1062-1070. PubMed ID: 34263288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.
    Guerrero-Bermúdez CA; Cardona-Cardona AF; Ariza-Parra EJ; Arostegui JI; Mensa-Vilaro A; Yague J; Vásquez G; Muñoz-Vahos CH
    Clin Rheumatol; 2022 Nov; 41(11):3565-3572. PubMed ID: 35986821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms.
    Xie Z; Chen EC; Mendez LM; Komrokji R; Zeidan AM
    Cancer J; 2023 May-Jun 01; 29(3):130-137. PubMed ID: 37195768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers.
    Gurnari C; Visconte V
    Leuk Res; 2023 Apr; 127():107038. PubMed ID: 36841022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance).
    Craven KE; Ewalt MD
    Clin Lab Med; 2023 Dec; 43(4):565-576. PubMed ID: 37865503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of clonal hematopoiesis in VEXAS syndrome.
    Gutierrez-Rodrigues F; Kusne Y; Fernandez J; Lasho T; Shalhoub R; Ma X; Alessi H; Finke C; Koster MJ; Mangaonkar A; Warrington KJ; Begna K; Xie Z; Ombrello AK; Viswanatha D; Ferrada M; Wilson L; Go R; Kourelis T; Reichard K; Olteanu H; Darden I; Hironaka D; Alemu L; Kajigaya S; Rosenzweig S; Calado RT; Groarke EM; Kastner DL; Calvo KR; Wu CO; Grayson PC; Young NS; Beck DB; Patel BA; Patnaik MM
    Blood; 2023 Jul; 142(3):244-259. PubMed ID: 37084382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEXAS syndrome with progression of MDS to MDS/MPN overlap syndrome.
    Neupane K; Jayarangaiah A; Zhang Y; Kumar A
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36549759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.
    Caponetti GC; Bagg A
    Int J Lab Hematol; 2020 Dec; 42(6):671-684. PubMed ID: 32757473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.
    Gondek LP; DeZern AE
    Lancet Haematol; 2020 Jan; 7(1):e73-e81. PubMed ID: 31810765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome.
    Lacombe V; Beucher A; Urbanski G; Le Corre Y; Cottin L; Croué A; Bouvier A
    Exp Hematol Oncol; 2022 Feb; 11(1):6. PubMed ID: 35172893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of plasma cell-free DNA for
    Gutierrez-Rodrigues F; Beerman I; Groarke EM; Patel BA; Spitofsky N; Dillon LW; Raffo DQ; Hourigan CS; Kajigaya S; Ferrucci L; Young NS
    Haematologica; 2022 Aug; 107(8):1815-1826. PubMed ID: 34587721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I investigate Clonal cytogenetic abnormalities of undetermined significance.
    Tang G; Medeiros LJ; Wang SA
    Int J Lab Hematol; 2018 Aug; 40(4):385-391. PubMed ID: 29624895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEXAS Syndrome: A Novelty in MDS Landscape.
    Templé M; Kosmider O
    Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
    Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
    Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEXAS syndrome: A dermatological perspective.
    Nguyen JK; Routledge D; van Der Weyden C; Blombery P; Angel CM; Johnson D; Goh MS; Lee A
    Australas J Dermatol; 2022 Nov; 63(4):488-492. PubMed ID: 36197697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.